Loading…
Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma
Abstract We evaluated the clinical outcomes and relapse patterns of 80 patients with primary sinonasal tract diffuse large B-cell lymphoma (SN-DLBCL) treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) chemotherapy at 22 institutions. A total of 59 (73.8%) patie...
Saved in:
| Published in: | Leukemia & lymphoma 2015-04, Vol.56 (4), p.1020-1026 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c418t-37aa38391c906faece6e1cc81951f94369c039d0413df989d2a2dc845ee1bde13 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c418t-37aa38391c906faece6e1cc81951f94369c039d0413df989d2a2dc845ee1bde13 |
| container_end_page | 1026 |
| container_issue | 4 |
| container_start_page | 1020 |
| container_title | Leukemia & lymphoma |
| container_volume | 56 |
| creator | Lee, Gyeong-Won Go, Se-Il Kim, Seok-Hyun Hong, Junshik Kim, Yu Ri Oh, Sukjoong Kim, Sung-Yong Do, Young Rok Lee, Hyewon Lee, Soon Il Bae, Sung Hwa Oh, Sung Yong Song, Moo Kon Lee, Won-Sik Lee, Bohee Kim, Jin Seok Kim, Min Kyoung Kang, Hye Jin Ahn, Jae-Sook Yhim, Ho-Young Kim, Hyo Jung Kim, Seok Jin Kim, Won Seog Suh, Cheolwon |
| description | Abstract
We evaluated the clinical outcomes and relapse patterns of 80 patients with primary sinonasal tract diffuse large B-cell lymphoma (SN-DLBCL) treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) chemotherapy at 22 institutions. A total of 59 (73.8%) patients received R-CHOP chemotherapy alone, whereas 21 (26.3%) were treated with R-CHOP followed by involved field radiotherapy (IFRT). In 73 patients with Ann Arbor stage I-II disease, no significant difference was found in the response rate or overall survival (OS) between R-CHOP alone (n = 52) and R-CHOP followed by IFRT (n = 21). Among 11 relapsed patients in this study, the most common pattern of relapse was local (n = 8, 11.8%), whereas central nervous system (CNS) relapse was observed in only one (1.9%) patient. These results suggest that patients with primary SN-DLBCL treated with R-CHOP have a relatively low CNS relapse rate and better OS compared to previous studies before the introduction of R. |
| doi_str_mv | 10.3109/10428194.2014.946027 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_infor</sourceid><recordid>TN_cdi_proquest_miscellaneous_1677890493</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1677890493</sourcerecordid><originalsourceid>FETCH-LOGICAL-c418t-37aa38391c906faece6e1cc81951f94369c039d0413df989d2a2dc845ee1bde13</originalsourceid><addsrcrecordid>eNp9UU2P0zAQzSIQuyz8A4R85LApduymMQcQVHysVIkDcI6m9qTxKrGLP7qbf4-jtkhc9mR7_ObNm_eK4jWjC86ofMeoqBomxaKiTCykqGm1elJcMVrJshKUP53voipnzGXxIoQ7SulS1tXz4rJaUi75kl1dXKwHY42CgbgUlRuRgNVk793OumACcR3ZQzRoYyD3Jvb5y4zgJxKMdRZCboweVCTadF0KSAbwOySfS4XDQIZp3PduhIxBiKiPFN7E9JBZtqWa1OAyIux7GI3GG6Ldg_Npa5SxN-RgrPImRGPPslBbE1x-qh5HF3v0sJ_eEyAhJj2R7URyjaydDc5Hk0bSOU9ux7xP5tqRn8kfzGFetiObk7aXxbMOhoCvTud18fvrl1_r7-Xmx7fb9adNqQRrYslXALzhkilJ6w5QYY1MqezuknVS8Fqq7KmmgnHdyUbqCiqtGrFEZFuNjF8Xb4-8WcyfhCG2owmzS2DRpdCyerVqJBWSZ6g4QpV3IXjs2pPrLaPtHH57Dr-dw2-P4ee2N6cJaTui_td0TjsDPh4BxmZfRrh3ftBthGlwvvNglQkz_aMjPvzH0CMMsVfgsb1zydts4OMa_wJPgNmZ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1677890493</pqid></control><display><type>article</type><title>Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Lee, Gyeong-Won ; Go, Se-Il ; Kim, Seok-Hyun ; Hong, Junshik ; Kim, Yu Ri ; Oh, Sukjoong ; Kim, Sung-Yong ; Do, Young Rok ; Lee, Hyewon ; Lee, Soon Il ; Bae, Sung Hwa ; Oh, Sung Yong ; Song, Moo Kon ; Lee, Won-Sik ; Lee, Bohee ; Kim, Jin Seok ; Kim, Min Kyoung ; Kang, Hye Jin ; Ahn, Jae-Sook ; Yhim, Ho-Young ; Kim, Hyo Jung ; Kim, Seok Jin ; Kim, Won Seog ; Suh, Cheolwon</creator><creatorcontrib>Lee, Gyeong-Won ; Go, Se-Il ; Kim, Seok-Hyun ; Hong, Junshik ; Kim, Yu Ri ; Oh, Sukjoong ; Kim, Sung-Yong ; Do, Young Rok ; Lee, Hyewon ; Lee, Soon Il ; Bae, Sung Hwa ; Oh, Sung Yong ; Song, Moo Kon ; Lee, Won-Sik ; Lee, Bohee ; Kim, Jin Seok ; Kim, Min Kyoung ; Kang, Hye Jin ; Ahn, Jae-Sook ; Yhim, Ho-Young ; Kim, Hyo Jung ; Kim, Seok Jin ; Kim, Won Seog ; Suh, Cheolwon ; Consortium for Improving Survival of Lymphoma (CISL) study group ; for the Consortium for Improving Survival of Lymphoma (CISL) study group</creatorcontrib><description>Abstract
We evaluated the clinical outcomes and relapse patterns of 80 patients with primary sinonasal tract diffuse large B-cell lymphoma (SN-DLBCL) treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) chemotherapy at 22 institutions. A total of 59 (73.8%) patients received R-CHOP chemotherapy alone, whereas 21 (26.3%) were treated with R-CHOP followed by involved field radiotherapy (IFRT). In 73 patients with Ann Arbor stage I-II disease, no significant difference was found in the response rate or overall survival (OS) between R-CHOP alone (n = 52) and R-CHOP followed by IFRT (n = 21). Among 11 relapsed patients in this study, the most common pattern of relapse was local (n = 8, 11.8%), whereas central nervous system (CNS) relapse was observed in only one (1.9%) patient. These results suggest that patients with primary SN-DLBCL treated with R-CHOP have a relatively low CNS relapse rate and better OS compared to previous studies before the introduction of R.</description><identifier>ISSN: 1042-8194</identifier><identifier>EISSN: 1029-2403</identifier><identifier>DOI: 10.3109/10428194.2014.946027</identifier><identifier>PMID: 25039351</identifier><language>eng</language><publisher>United States: Informa Healthcare</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Cyclophosphamide - administration & dosage ; Diffuse large cell lymphomas ; Disease-Free Survival ; Doxorubicin - administration & dosage ; Female ; Humans ; Lymphoma, Large B-Cell, Diffuse - drug therapy ; Lymphoma, Large B-Cell, Diffuse - pathology ; Male ; Middle Aged ; Multivariate Analysis ; nasal cavities ; Neoplasm Recurrence, Local ; Neoplasm Staging ; paranasal sinus ; Paranasal Sinus Neoplasms - drug therapy ; Prednisone - administration & dosage ; Prognosis ; rituximab ; Rituximab - administration & dosage ; Treatment Outcome ; Vincristine - administration & dosage</subject><ispartof>Leukemia & lymphoma, 2015-04, Vol.56 (4), p.1020-1026</ispartof><rights>2014 Informa UK, Ltd. 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c418t-37aa38391c906faece6e1cc81951f94369c039d0413df989d2a2dc845ee1bde13</citedby><cites>FETCH-LOGICAL-c418t-37aa38391c906faece6e1cc81951f94369c039d0413df989d2a2dc845ee1bde13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25039351$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Gyeong-Won</creatorcontrib><creatorcontrib>Go, Se-Il</creatorcontrib><creatorcontrib>Kim, Seok-Hyun</creatorcontrib><creatorcontrib>Hong, Junshik</creatorcontrib><creatorcontrib>Kim, Yu Ri</creatorcontrib><creatorcontrib>Oh, Sukjoong</creatorcontrib><creatorcontrib>Kim, Sung-Yong</creatorcontrib><creatorcontrib>Do, Young Rok</creatorcontrib><creatorcontrib>Lee, Hyewon</creatorcontrib><creatorcontrib>Lee, Soon Il</creatorcontrib><creatorcontrib>Bae, Sung Hwa</creatorcontrib><creatorcontrib>Oh, Sung Yong</creatorcontrib><creatorcontrib>Song, Moo Kon</creatorcontrib><creatorcontrib>Lee, Won-Sik</creatorcontrib><creatorcontrib>Lee, Bohee</creatorcontrib><creatorcontrib>Kim, Jin Seok</creatorcontrib><creatorcontrib>Kim, Min Kyoung</creatorcontrib><creatorcontrib>Kang, Hye Jin</creatorcontrib><creatorcontrib>Ahn, Jae-Sook</creatorcontrib><creatorcontrib>Yhim, Ho-Young</creatorcontrib><creatorcontrib>Kim, Hyo Jung</creatorcontrib><creatorcontrib>Kim, Seok Jin</creatorcontrib><creatorcontrib>Kim, Won Seog</creatorcontrib><creatorcontrib>Suh, Cheolwon</creatorcontrib><creatorcontrib>Consortium for Improving Survival of Lymphoma (CISL) study group</creatorcontrib><creatorcontrib>for the Consortium for Improving Survival of Lymphoma (CISL) study group</creatorcontrib><title>Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma</title><title>Leukemia & lymphoma</title><addtitle>Leuk Lymphoma</addtitle><description>Abstract
We evaluated the clinical outcomes and relapse patterns of 80 patients with primary sinonasal tract diffuse large B-cell lymphoma (SN-DLBCL) treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) chemotherapy at 22 institutions. A total of 59 (73.8%) patients received R-CHOP chemotherapy alone, whereas 21 (26.3%) were treated with R-CHOP followed by involved field radiotherapy (IFRT). In 73 patients with Ann Arbor stage I-II disease, no significant difference was found in the response rate or overall survival (OS) between R-CHOP alone (n = 52) and R-CHOP followed by IFRT (n = 21). Among 11 relapsed patients in this study, the most common pattern of relapse was local (n = 8, 11.8%), whereas central nervous system (CNS) relapse was observed in only one (1.9%) patient. These results suggest that patients with primary SN-DLBCL treated with R-CHOP have a relatively low CNS relapse rate and better OS compared to previous studies before the introduction of R.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Diffuse large cell lymphomas</subject><subject>Disease-Free Survival</subject><subject>Doxorubicin - administration & dosage</subject><subject>Female</subject><subject>Humans</subject><subject>Lymphoma, Large B-Cell, Diffuse - drug therapy</subject><subject>Lymphoma, Large B-Cell, Diffuse - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>nasal cavities</subject><subject>Neoplasm Recurrence, Local</subject><subject>Neoplasm Staging</subject><subject>paranasal sinus</subject><subject>Paranasal Sinus Neoplasms - drug therapy</subject><subject>Prednisone - administration & dosage</subject><subject>Prognosis</subject><subject>rituximab</subject><subject>Rituximab - administration & dosage</subject><subject>Treatment Outcome</subject><subject>Vincristine - administration & dosage</subject><issn>1042-8194</issn><issn>1029-2403</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNp9UU2P0zAQzSIQuyz8A4R85LApduymMQcQVHysVIkDcI6m9qTxKrGLP7qbf4-jtkhc9mR7_ObNm_eK4jWjC86ofMeoqBomxaKiTCykqGm1elJcMVrJshKUP53voipnzGXxIoQ7SulS1tXz4rJaUi75kl1dXKwHY42CgbgUlRuRgNVk793OumACcR3ZQzRoYyD3Jvb5y4zgJxKMdRZCboweVCTadF0KSAbwOySfS4XDQIZp3PduhIxBiKiPFN7E9JBZtqWa1OAyIux7GI3GG6Ldg_Npa5SxN-RgrPImRGPPslBbE1x-qh5HF3v0sJ_eEyAhJj2R7URyjaydDc5Hk0bSOU9ux7xP5tqRn8kfzGFetiObk7aXxbMOhoCvTud18fvrl1_r7-Xmx7fb9adNqQRrYslXALzhkilJ6w5QYY1MqezuknVS8Fqq7KmmgnHdyUbqCiqtGrFEZFuNjF8Xb4-8WcyfhCG2owmzS2DRpdCyerVqJBWSZ6g4QpV3IXjs2pPrLaPtHH57Dr-dw2-P4ee2N6cJaTui_td0TjsDPh4BxmZfRrh3ftBthGlwvvNglQkz_aMjPvzH0CMMsVfgsb1zydts4OMa_wJPgNmZ</recordid><startdate>20150401</startdate><enddate>20150401</enddate><creator>Lee, Gyeong-Won</creator><creator>Go, Se-Il</creator><creator>Kim, Seok-Hyun</creator><creator>Hong, Junshik</creator><creator>Kim, Yu Ri</creator><creator>Oh, Sukjoong</creator><creator>Kim, Sung-Yong</creator><creator>Do, Young Rok</creator><creator>Lee, Hyewon</creator><creator>Lee, Soon Il</creator><creator>Bae, Sung Hwa</creator><creator>Oh, Sung Yong</creator><creator>Song, Moo Kon</creator><creator>Lee, Won-Sik</creator><creator>Lee, Bohee</creator><creator>Kim, Jin Seok</creator><creator>Kim, Min Kyoung</creator><creator>Kang, Hye Jin</creator><creator>Ahn, Jae-Sook</creator><creator>Yhim, Ho-Young</creator><creator>Kim, Hyo Jung</creator><creator>Kim, Seok Jin</creator><creator>Kim, Won Seog</creator><creator>Suh, Cheolwon</creator><general>Informa Healthcare</general><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20150401</creationdate><title>Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma</title><author>Lee, Gyeong-Won ; Go, Se-Il ; Kim, Seok-Hyun ; Hong, Junshik ; Kim, Yu Ri ; Oh, Sukjoong ; Kim, Sung-Yong ; Do, Young Rok ; Lee, Hyewon ; Lee, Soon Il ; Bae, Sung Hwa ; Oh, Sung Yong ; Song, Moo Kon ; Lee, Won-Sik ; Lee, Bohee ; Kim, Jin Seok ; Kim, Min Kyoung ; Kang, Hye Jin ; Ahn, Jae-Sook ; Yhim, Ho-Young ; Kim, Hyo Jung ; Kim, Seok Jin ; Kim, Won Seog ; Suh, Cheolwon</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c418t-37aa38391c906faece6e1cc81951f94369c039d0413df989d2a2dc845ee1bde13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Diffuse large cell lymphomas</topic><topic>Disease-Free Survival</topic><topic>Doxorubicin - administration & dosage</topic><topic>Female</topic><topic>Humans</topic><topic>Lymphoma, Large B-Cell, Diffuse - drug therapy</topic><topic>Lymphoma, Large B-Cell, Diffuse - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>nasal cavities</topic><topic>Neoplasm Recurrence, Local</topic><topic>Neoplasm Staging</topic><topic>paranasal sinus</topic><topic>Paranasal Sinus Neoplasms - drug therapy</topic><topic>Prednisone - administration & dosage</topic><topic>Prognosis</topic><topic>rituximab</topic><topic>Rituximab - administration & dosage</topic><topic>Treatment Outcome</topic><topic>Vincristine - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Gyeong-Won</creatorcontrib><creatorcontrib>Go, Se-Il</creatorcontrib><creatorcontrib>Kim, Seok-Hyun</creatorcontrib><creatorcontrib>Hong, Junshik</creatorcontrib><creatorcontrib>Kim, Yu Ri</creatorcontrib><creatorcontrib>Oh, Sukjoong</creatorcontrib><creatorcontrib>Kim, Sung-Yong</creatorcontrib><creatorcontrib>Do, Young Rok</creatorcontrib><creatorcontrib>Lee, Hyewon</creatorcontrib><creatorcontrib>Lee, Soon Il</creatorcontrib><creatorcontrib>Bae, Sung Hwa</creatorcontrib><creatorcontrib>Oh, Sung Yong</creatorcontrib><creatorcontrib>Song, Moo Kon</creatorcontrib><creatorcontrib>Lee, Won-Sik</creatorcontrib><creatorcontrib>Lee, Bohee</creatorcontrib><creatorcontrib>Kim, Jin Seok</creatorcontrib><creatorcontrib>Kim, Min Kyoung</creatorcontrib><creatorcontrib>Kang, Hye Jin</creatorcontrib><creatorcontrib>Ahn, Jae-Sook</creatorcontrib><creatorcontrib>Yhim, Ho-Young</creatorcontrib><creatorcontrib>Kim, Hyo Jung</creatorcontrib><creatorcontrib>Kim, Seok Jin</creatorcontrib><creatorcontrib>Kim, Won Seog</creatorcontrib><creatorcontrib>Suh, Cheolwon</creatorcontrib><creatorcontrib>Consortium for Improving Survival of Lymphoma (CISL) study group</creatorcontrib><creatorcontrib>for the Consortium for Improving Survival of Lymphoma (CISL) study group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Leukemia & lymphoma</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Gyeong-Won</au><au>Go, Se-Il</au><au>Kim, Seok-Hyun</au><au>Hong, Junshik</au><au>Kim, Yu Ri</au><au>Oh, Sukjoong</au><au>Kim, Sung-Yong</au><au>Do, Young Rok</au><au>Lee, Hyewon</au><au>Lee, Soon Il</au><au>Bae, Sung Hwa</au><au>Oh, Sung Yong</au><au>Song, Moo Kon</au><au>Lee, Won-Sik</au><au>Lee, Bohee</au><au>Kim, Jin Seok</au><au>Kim, Min Kyoung</au><au>Kang, Hye Jin</au><au>Ahn, Jae-Sook</au><au>Yhim, Ho-Young</au><au>Kim, Hyo Jung</au><au>Kim, Seok Jin</au><au>Kim, Won Seog</au><au>Suh, Cheolwon</au><aucorp>Consortium for Improving Survival of Lymphoma (CISL) study group</aucorp><aucorp>for the Consortium for Improving Survival of Lymphoma (CISL) study group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma</atitle><jtitle>Leukemia & lymphoma</jtitle><addtitle>Leuk Lymphoma</addtitle><date>2015-04-01</date><risdate>2015</risdate><volume>56</volume><issue>4</issue><spage>1020</spage><epage>1026</epage><pages>1020-1026</pages><issn>1042-8194</issn><eissn>1029-2403</eissn><abstract>Abstract
We evaluated the clinical outcomes and relapse patterns of 80 patients with primary sinonasal tract diffuse large B-cell lymphoma (SN-DLBCL) treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) chemotherapy at 22 institutions. A total of 59 (73.8%) patients received R-CHOP chemotherapy alone, whereas 21 (26.3%) were treated with R-CHOP followed by involved field radiotherapy (IFRT). In 73 patients with Ann Arbor stage I-II disease, no significant difference was found in the response rate or overall survival (OS) between R-CHOP alone (n = 52) and R-CHOP followed by IFRT (n = 21). Among 11 relapsed patients in this study, the most common pattern of relapse was local (n = 8, 11.8%), whereas central nervous system (CNS) relapse was observed in only one (1.9%) patient. These results suggest that patients with primary SN-DLBCL treated with R-CHOP have a relatively low CNS relapse rate and better OS compared to previous studies before the introduction of R.</abstract><cop>United States</cop><pub>Informa Healthcare</pub><pmid>25039351</pmid><doi>10.3109/10428194.2014.946027</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1042-8194 |
| ispartof | Leukemia & lymphoma, 2015-04, Vol.56 (4), p.1020-1026 |
| issn | 1042-8194 1029-2403 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1677890493 |
| source | Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list) |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cyclophosphamide - administration & dosage Diffuse large cell lymphomas Disease-Free Survival Doxorubicin - administration & dosage Female Humans Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - pathology Male Middle Aged Multivariate Analysis nasal cavities Neoplasm Recurrence, Local Neoplasm Staging paranasal sinus Paranasal Sinus Neoplasms - drug therapy Prednisone - administration & dosage Prognosis rituximab Rituximab - administration & dosage Treatment Outcome Vincristine - administration & dosage |
| title | Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T11%3A13%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_infor&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20outcome%20and%20prognosis%20of%20patients%20with%20primary%20sinonasal%20tract%20diffuse%20large%20B-cell%20lymphoma%20treated%20with%20rituximab-cyclophosphamide,%20doxorubicin,%20vincristine%20and%20prednisone%20chemotherapy:%20a%20study%20by%20the%20Consortium%20for%20Improving%20Survival%20of%20Lymphoma&rft.jtitle=Leukemia%20&%20lymphoma&rft.au=Lee,%20Gyeong-Won&rft.aucorp=Consortium%20for%20Improving%20Survival%20of%20Lymphoma%20(CISL)%20study%20group&rft.date=2015-04-01&rft.volume=56&rft.issue=4&rft.spage=1020&rft.epage=1026&rft.pages=1020-1026&rft.issn=1042-8194&rft.eissn=1029-2403&rft_id=info:doi/10.3109/10428194.2014.946027&rft_dat=%3Cproquest_infor%3E1677890493%3C/proquest_infor%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c418t-37aa38391c906faece6e1cc81951f94369c039d0413df989d2a2dc845ee1bde13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1677890493&rft_id=info:pmid/25039351&rfr_iscdi=true |